Karyotypic detection of chromosomal 16 abnormalities classically assoc
iated with AML M4Eo can be difficult. Characterization of the two gene
s involved in the inv(16)(p13q22), CBF beta and MYH11, has allowed the
detection of fusion transcripts by reverse-transcriptase polymerase c
hain reaction (RT-PCR). We have analyzed CBF beta-MYH11 fusion transcr
ipts by RT-PCR in myelomonocytic leukemias, with or without eosinophil
ia, to determine whether their presence correlates with morphology. Fi
fty-three cases (11 AML M4Eo; 1 AML M4 with atypical abnormal eosinoph
ils (AML M4 ''Eo''); 29 AML M4; 8 AML M5; 3 CMML; and 1 AML M2 with eo
sinophilia) were analyzed. All 11 typical AML M4Eo were CBF beta-MYH11
positive. The single case of AML M4 with distinctive eosinophil abnor
malities was negative by karyotype, RT-PCR and fluorescent in situ hyb
ridization (FISH). Three of 29 (10%) AML M4 without abnormal eosinophi
ls were CBF beta-MYH11 positive, 1 of which did not show any apparent
chromosome 16 abnormalities by classical metaphase analysis (2 not tes
ted). Both cases tested also showed MYH11 genomic rearrangement. None
of the other leukemias were RT-PCR positive. Follow-up of three patien
ts showed residual positivity in apparent complete remission. These da
ta show that CBF beta-MYH11 fusion transcripts occur not only in the v
ast majority of typical AML M4Eo, but also in approximate to 10% of AM
L M4 without eosinophilic abnormalities, a much higher incidence than
the sporadic reports of chromosome 16 abnormalities in AML M4 would su
ggest. Taken together with the detection of CBF beta-MYH11 transcripts
in the absence of apparent chromosome 16 abnormalities by classical b
anding techniques, these data show that additional screening by either
RT-PCR or FISH should be performed in all AML M4, regardless of morph
ologic features, to allow accurate evaluation of the prognostic import
ance of this fusion transcript. (C) 1995 by The American Society of He
matology.